The New England journal of medicine | 3 Sep 2019
SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, F Martinez, M Packer, MA Pfeffer, B Pieske, MM Redfield, JL Rouleau, DJ van Veldhuisen, F Zannad, MR Zile, AS Desai, B Claggett, PS Jhund, SA Boytsov, J Comin-Colet, J Cleland, HD Düngen, E Goncalvesova, T Katova, JF Kerr Saraiva, M Lelonek, B Merkely, M Senni, SJ Shah, J Zhou, AR Rizkala, J Gong, VC Shi and MP Lefkowitz
The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.
* Data courtesy of Altmetric.com